320 related articles for article (PubMed ID: 15833814)
1. The gene expression signatures of melanoma progression.
Haqq C; Nosrati M; Sudilovsky D; Crothers J; Khodabakhsh D; Pulliam BL; Federman S; Miller JR; Allen RE; Singer MI; Leong SP; Ljung BM; Sagebiel RW; Kashani-Sabet M
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6092-7. PubMed ID: 15833814
[TBL] [Abstract][Full Text] [Related]
2. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.
Jaeger J; Koczan D; Thiesen HJ; Ibrahim SM; Gross G; Spang R; Kunz M
Clin Cancer Res; 2007 Feb; 13(3):806-15. PubMed ID: 17289871
[TBL] [Abstract][Full Text] [Related]
3. Mutations of the BRAF gene in benign and malignant melanocytic lesions.
Yazdi AS; Palmedo G; Flaig MJ; Puchta U; Reckwerth A; Rütten A; Mentzel T; Hügel H; Hantschke M; Schmid-Wendtner MH; Kutzner H; Sander CA
J Invest Dermatol; 2003 Nov; 121(5):1160-2. PubMed ID: 14708620
[TBL] [Abstract][Full Text] [Related]
4. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?
Woenckhaus C; Giebel J; Failing K; Fenic I; Dittberner T; Poetsch M
J Pathol; 2003 Oct; 201(2):278-87. PubMed ID: 14517845
[TBL] [Abstract][Full Text] [Related]
5. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma.
Demunter A; Stas M; Degreef H; De Wolf-Peeters C; van den Oord JJ
J Invest Dermatol; 2001 Dec; 117(6):1483-9. PubMed ID: 11886512
[TBL] [Abstract][Full Text] [Related]
6. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas.
Smith AP; Hoek K; Becker D
Cancer Biol Ther; 2005 Sep; 4(9):1018-29. PubMed ID: 16251803
[TBL] [Abstract][Full Text] [Related]
7. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
[TBL] [Abstract][Full Text] [Related]
8. DNA-methylation profiling distinguishes malignant melanomas from benign nevi.
Conway K; Edmiston SN; Khondker ZS; Groben PA; Zhou X; Chu H; Kuan PF; Hao H; Carson C; Berwick M; Olilla DW; Thomas NE
Pigment Cell Melanoma Res; 2011 Apr; 24(2):352-60. PubMed ID: 21375697
[TBL] [Abstract][Full Text] [Related]
9. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
10. cDNA-array profiling of melanomas and paired melanocyte cultures.
Mischiati C; Natali PG; Sereni A; Sibilio L; Giorda E; Cappellacci S; Nicotra MR; Mariani G; Di Filippo F; Catricalà C; Gambari R; Grammatico P; Giacomini P
J Cell Physiol; 2006 Jun; 207(3):697-705. PubMed ID: 16523488
[TBL] [Abstract][Full Text] [Related]
11. High frequency of BRAF mutations in nevi.
Pollock PM; Harper UL; Hansen KS; Yudt LM; Stark M; Robbins CM; Moses TY; Hostetter G; Wagner U; Kakareka J; Salem G; Pohida T; Heenan P; Duray P; Kallioniemi O; Hayward NK; Trent JM; Meltzer PS
Nat Genet; 2003 Jan; 33(1):19-20. PubMed ID: 12447372
[TBL] [Abstract][Full Text] [Related]
12. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype.
Albino AP; Nanus DM; Mentle IR; Cordon-Cardo C; McNutt NS; Bressler J; Andreeff M
Oncogene; 1989 Nov; 4(11):1363-74. PubMed ID: 2682463
[TBL] [Abstract][Full Text] [Related]
13. RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas.
Kunz M; Löffler-Wirth H; Dannemann M; Willscher E; Doose G; Kelso J; Kottek T; Nickel B; Hopp L; Landsberg J; Hoffmann S; Tüting T; Zigrino P; Mauch C; Utikal J; Ziemer M; Schulze HJ; Hölzel M; Roesch A; Kneitz S; Meierjohann S; Bosserhoff A; Binder H; Schartl M
Oncogene; 2018 Nov; 37(47):6136-6151. PubMed ID: 29995873
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
Jönsson G; Busch C; Knappskog S; Geisler J; Miletic H; Ringnér M; Lillehaug JR; Borg A; Lønning PE
Clin Cancer Res; 2010 Jul; 16(13):3356-67. PubMed ID: 20460471
[TBL] [Abstract][Full Text] [Related]
15. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
[TBL] [Abstract][Full Text] [Related]
16. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
[TBL] [Abstract][Full Text] [Related]
17. Genetic similarities between Spitz nevus and Spitzoid melanoma in children.
Gill M; Cohen J; Renwick N; Mones JM; Silvers DN; Celebi JT
Cancer; 2004 Dec; 101(11):2636-40. PubMed ID: 15503312
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of primary cutaneous melanoma.
Winnepenninckx V; Van den Oord JJ
Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
[TBL] [Abstract][Full Text] [Related]
19. Telomerase activity and expression of apoptosis and anti-apoptosis regulators in the progression pathway of human melanoma.
Yang P; Becker D
Int J Oncol; 2000 Nov; 17(5):913-9. PubMed ID: 11029492
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.
Dai DL; Martinka M; Li G
J Clin Oncol; 2005 Mar; 23(7):1473-82. PubMed ID: 15735123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
